"Shifting Landscape: The Future of Weight Loss Drugs in 2024"

Prominent weight-loss drugs, known as GLP-1s, made by Novo Nordisk and Eli Lilly, may not have as much lasting impact on healthcare in 2024 as previously expected. Analysts are predicting less need for medtech devices and surgeries due to the popularity of these drugs, but recent commentary suggests a shift away from the initial fear and panic surrounding their impact. Fast-food and fast-casual chains' valuation rebound is credited to a cooling GLP-1 narrative, with industry veterans noting that accessibility to these drugs is difficult for lower-income consumers and that healthier alternatives may boost business. The uptake of these drugs, accessibility, side effects, and production constraints are still key factors in determining their long-term impact.